Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоатла, Инк.filedCriticalБайоатла, Инк.
Priority claimed from PCT/US2019/058066external-prioritypatent/WO2020092155A1/en
Publication of EA202191187A1publicationCriticalpatent/EA202191187A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Полипептид, имеющий вариабельную область тяжелой цепи и/или вариабельную область легкой цепи, который специфически связывается с белком CTLA4, а также антитела и фрагменты антител, содержащие вариабельную область тяжелой цепи и/или вариабельную область легкой цепи, которые связываются с белком CTLA4. Также предложены фармацевтические композиции и наборы, содержащие полипептид или антитела и фрагменты антител, содержащие полипептид.A polypeptide having a heavy chain variable region and / or a light chain variable region that specifically binds to a CTLA4 protein, as well as antibodies and antibody fragments containing a heavy chain variable region and / or a light chain variable region that bind to a CTLA4 protein. Also provided are pharmaceutical compositions and kits containing the polypeptide or antibodies and antibody fragments containing the polypeptide.
EA202191187A2019-03-262019-10-25
ANTIBODIES TO CTLA4, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND THEIR APPLICATION
EA202191187A1
(en)
STABILITIES OF ANTI-CTLA4 ANTIBODIES, SEPARATELY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF APPLICATION